The evolving global market for obesity treatments, reflecting as it does the different cultures, driving forces, regulatory environments and other market conditions, shows important variations from region to region.
Considering that the U.S. and European markets share many market dynamics — even with different regulatory hurdles, the US and the EU are more alike than different — it is worth considering the difference between Europe and another large market/region, the Asia-Pacific markets, which comprise Japan, Korea, China, India and Australia.
Obesity and its treatment in well-developed economies like the EU and Asia-Pacific are affected by the differences in clinical incidence of obesity, which do show ethnic differences, the social perceptions of obesity and the extent to which their healthcare systems have responded to adopt the various treatment options. As a result, markets like the EU and Asia-Pacific show stark differences in their current and forecast drug and device totals among all options.
Below is illustrated the 2011 comparison of the the EU with Asia-Pacific drug and device treatments for obesity and, below this, is the similar 2019 forecast.
Source: MedMarket Diligence, LLC; Report #S835, "Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019."